ZYUS Announces Database Lock for its Phase 1 First-in-Human Clinical Trial

49

Phase 1 was conducted to assess the safety, tolerability, and pharmacokinetics of ZYUS’ lead drug product candidate in healthy adult participants

SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS” or the “Company”), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the successful completion of database lock for its Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of Trichomylin® softgel capsules in healthy adult participants in Australia. The dataset has been transferred to the Company’s independent Clinical Research Organization for statistical analysis. Reaching a database lock also allows ZYUS to begin preparation for its Phase 2a clinical trial, expected to commence in 2023.

This achievement marks an important milestone in ZYUS’ mission, to develop cannabinoid-based pharmaceutical drug products with meticulous scientific rigor,” said ZYUS CEO Brent Zettl. “We continue to pursue our clinical studies in osteoarthritic pain as previously announced. We believe the results of this Phase 1 clinical trial will bring us another step closer to providing patients with a regulatory-approved cannabinoid-based prescription drug for the alleviation of chronic pain.”

RELATED:  Flora Growth Acquires CBD Brand Masaya

About ZYUS Life Sciences Inc.: ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and innovative exempt market therapeutics. Through clinical research, ZYUS is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, ZYUS is dedicated to delivering high quality, cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The ZYUS vision is to elevate cannabinoid-based therapeutics as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives around the world. ZYUS: Advancing the Science of Well-Being. For additional information, visit www.zyus.com.

Forward-Looking Information:

This news release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to, expectations with respect to our business plans, product lines, research activities (including without limitation, the clinical progress of Trichomylin®, the availability of clinical trial results) and the prospects for regulatory approval, commercializing or selling any product or drug candidates.

RELATED:  Proposed Settlement Reached in 2016 Class Action

Often, but not always, forward-looking statements can be identified by the use of words such as “expects,” “expected,” “expectation,” “anticipates,” “believes,” “intends,” “estimates,” “predicts,” “continues,” “potential,” “targeted,” “plans,” “possible” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” “would” or “should” occur or be achieved, or the negative of these terms or other comparable terminology. Forward-looking statements are based on certain assumptions including assumptions relating to the ability of ZYUS to continue to ensure product availability, consistency and quality through robust procurement, manufacturing and testing processes, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified , including risks related to: potential impacts due to the COVID-19; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to secure regulatory approval of its product candidates, and the success of future product advancements, including the success of future clinical trials. Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements and readers should not place undue reliance on the forward-looking statements and information contained in this press release.

RELATED:  Aelis Farma Announces Positive Results From Its Safety Trials in Healthy Volunteers and the Authorization to Start the First Trial in People with Down Syndrome with AEF0217, its Drug Candidate for the Treatment of Cognitive Disorders

Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS does not assume any obligation to update or revise any forward-looking statements or information, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

Contacts

ZYUS Media Inquiries

media@zyus.com
1-833-651-7723

ZYUS Investor Relations

Bruce M. Mann

investors@zyus.com
1-888-651-9987